CLOs on the Move

Garuda Therapeutics

www.garudatx.com

 
Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.garudatx.com
  • 215 First Street Suites 340-350
    Cambridge, MA USA 02142
  • Phone: 559.594.4380

Executives

Name Title Contact Details
James Desiderio
Chief Regulatory Officer Profile

Similar Companies

Eiger BioPharmaceuticals

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.

Chiasma

Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.

Fluke Biomedical

Fluke Biomedical Corp. is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TwinStrand Biosciences

At TwinStrand Biosciences we are using Duplex Sequencing ™ Technology to detect ultra-rare variants that are invisible by other sequencing approaches. We are applying our technology to a new generation of high-accuracy clinical diagnostics and innovative tools for scientific discovery.